Pacific Edge Limited reported total revenue of $7.1 million for the first half of fiscal year 2026, a decrease of 42.8% compared to the second half of 2025. Test volumes totaled 13,191 globally, down 10.1% from the previous period, with US total tests at 10,693 (down 13.1%) and APAC total tests at 2,498 (up 5.4%). Commercial test volumes declined 15.9% to 10,371. Net loss after tax was $19.1 million, compared to a net loss of $15.4 million in the previous half. Cash and cash equivalents stood at $22.1 million. The company maintained its US market presence following a loss of coverage and noted ongoing efforts related to Medicare appeals and re-coverage. Pacific Edge is also considering capital initiatives to address a longer-than-expected Medicare re-coverage timeline and highlighted a draft CMS pricing for its Triage Plus test at $1,328 per test.